NEW YORK, April 11, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on SNDX, TLGT, RARE, and VBLT which can be accessed for free by signing up to www.wallstequities.com/registration. Featured today on WallStEquities.com is the global Biotechnology market, which is mainly driven by the surge in the demand for food, depleting natural resources, government regulatory support, and technological advancements of various solutions to counter fatal diseases. Under evaluation this morning are these four equities: Syndax Pharmaceuticals Inc. (NASDAQ: SNDX), Teligent Inc. (NASDAQ: TLGT), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Vascular Biogenics Ltd (NASDAQ: VBLT). All you have to do is sign up today for this free limited time offer by clicking the link below. www.wallstequities.com/registration
Syndax Pharmaceuticals
Shares in Syndax Pharmaceuticals Inc. rose 2.37%, ending Tuesday's trading session at $11.44. The stock recorded a trading volume of 242,540 shares. The Company's shares have gained 16.38% in the last month and 27.39% over the last three months. The stock is trading 1.45% and 3.08% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Syndax Pharma, which develops a therapy that enhances checkpoint immuno-oncology drugs, have a Relative Strength Index (RSI) of 43.92. Get the full research report on SNDX for free by clicking below at: www.wallstequities.com/registration/?symbol=SNDX
Teligent
Buena, New Jersey-based Teligent Inc.'s stock climbed 1.12%, closing the day at $2.72 with a total trading volume of 478,151 shares. The Company's shares have advanced 1.12% in the past month. The stock is trading 9.73% below its 50-day moving average. Additionally, shares of Teligent, which develops, manufactures, and markets topical formulations in the US, have an RSI of 39.14.
On April 06th, 2018, Teligent announced that its abbreviated new drug application (ANDA) for Ciclopirox Shampoo, 1%, has received approval from the US FDA. This is the Company's third approval for 2018 and its twenty-second approval from its internally-developed pipeline of topical generic pharmaceutical medicines. Based on recent IQVIA data from January 2018, the total addressable market for this product is approximately $13.5 million. Access the free research report on TLGT now by signing up at: www.wallstequities.com/registration/?symbol=TLGT
Ultragenyx Pharmaceutical
On Tuesday, shares in Novato, California headquartered Ultragenyx Pharmaceutical Inc. recorded a trading volume of 600,833 shares, which was higher than their three months average volume of 579,440 shares. The stock ended the day 3.87% higher at $52.67. The Company's shares have advanced 9.18% in the previous three months. The stock is trading above its 50-day moving average by 4.80%. Furthermore, shares of Ultragenyx Pharma, which focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the US, have an RSI of 56.39.
On March 22nd, 2018, research firm Piper Jaffray resumed its 'Overweight' rating on the Company's stock, with a target price of $67 per share. Are you already registered with Wall St. Equities? Do so now for free, and get the report on RARE at: www.wallstequities.com/registration/?symbol=RARE
Vascular Biogenics
Or Yehuda, Israel headquartered Vascular Biogenics Ltd's stock jumped 7.14%, finishing yesterday's session at $2.25 with a total trading volume of 176,382 shares. The stock is trading below their 50-day moving average by 51.59%. Shares of the Company, which engages in the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases, have an RSI of 29.60.
On April 09th, 2018, Vascular Biogenics, operating as VBL Therapeutics, announced that it has been awarded a grant of 8.9 million New Israeli Shekels (approximately $2.5 million) by the Israel Innovation Authority. The funds will support the development of the Company's lead candidate VB-111 and its Vascular Targeting System platform for therapeutic gene therapy. Aspiring Member, please take a moment to register below for your free research report on VBLT at: www.wallstequities.com/registration/?symbol=VBLT
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Advertisement
Syndax Pharmaceuticals
Shares in Syndax Pharmaceuticals Inc. rose 2.37%, ending Tuesday's trading session at $11.44. The stock recorded a trading volume of 242,540 shares. The Company's shares have gained 16.38% in the last month and 27.39% over the last three months. The stock is trading 1.45% and 3.08% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Syndax Pharma, which develops a therapy that enhances checkpoint immuno-oncology drugs, have a Relative Strength Index (RSI) of 43.92. Get the full research report on SNDX for free by clicking below at: www.wallstequities.com/registration/?symbol=SNDX
Advertisement
Teligent
Buena, New Jersey-based Teligent Inc.'s stock climbed 1.12%, closing the day at $2.72 with a total trading volume of 478,151 shares. The Company's shares have advanced 1.12% in the past month. The stock is trading 9.73% below its 50-day moving average. Additionally, shares of Teligent, which develops, manufactures, and markets topical formulations in the US, have an RSI of 39.14.
On April 06th, 2018, Teligent announced that its abbreviated new drug application (ANDA) for Ciclopirox Shampoo, 1%, has received approval from the US FDA. This is the Company's third approval for 2018 and its twenty-second approval from its internally-developed pipeline of topical generic pharmaceutical medicines. Based on recent IQVIA data from January 2018, the total addressable market for this product is approximately $13.5 million. Access the free research report on TLGT now by signing up at: www.wallstequities.com/registration/?symbol=TLGT
Ultragenyx Pharmaceutical
On Tuesday, shares in Novato, California headquartered Ultragenyx Pharmaceutical Inc. recorded a trading volume of 600,833 shares, which was higher than their three months average volume of 579,440 shares. The stock ended the day 3.87% higher at $52.67. The Company's shares have advanced 9.18% in the previous three months. The stock is trading above its 50-day moving average by 4.80%. Furthermore, shares of Ultragenyx Pharma, which focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the US, have an RSI of 56.39.
On March 22nd, 2018, research firm Piper Jaffray resumed its 'Overweight' rating on the Company's stock, with a target price of $67 per share. Are you already registered with Wall St. Equities? Do so now for free, and get the report on RARE at: www.wallstequities.com/registration/?symbol=RARE
Vascular Biogenics
Or Yehuda, Israel headquartered Vascular Biogenics Ltd's stock jumped 7.14%, finishing yesterday's session at $2.25 with a total trading volume of 176,382 shares. The stock is trading below their 50-day moving average by 51.59%. Shares of the Company, which engages in the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases, have an RSI of 29.60.
On April 09th, 2018, Vascular Biogenics, operating as VBL Therapeutics, announced that it has been awarded a grant of 8.9 million New Israeli Shekels (approximately $2.5 million) by the Israel Innovation Authority. The funds will support the development of the Company's lead candidate VB-111 and its Vascular Targeting System platform for therapeutic gene therapy. Aspiring Member, please take a moment to register below for your free research report on VBLT at: www.wallstequities.com/registration/?symbol=VBLT
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----syndax-pharma-teligent-ultragenyx-pharma-and-vascular-biogenics-300627929.html
SOURCE Wall St. Equities
